Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I have been in this share for a few years myself and am comfortable that the ‘jam’ will arrive within a reasonable timeframe that suits my investment objectives.
Ctw2014 be careful of the "jam tomorrow" mantra!!!
I have been in this share for about 2 years and am still a fan of its products/potential. This year certainly seems to have many more realistic monetisation announcements but as I keep saying re this share (sorry) the lack of director buying on what seems a VERY VERY cheap share price considering the announcements they are making has stopped me from topping up.
Announcements VERY RARELY come with any hard figures (most frustratingly with the bread packaging contract which should be a game changer).
Me and MANY MANY on here who have held for longer have yet to see the jam!!!!
Good to see SYM promoting the company via outlets such as a proactive. Word needs to get out there about what a promising little company this is. Still very much off the radar of most investors.
Should break the 20’s today.
Yes, what a great little share. Onwards and upwards.
RNS OUT
Agreement for Middle East manufacturing, more excellent news from the company, it’s about time this is reflected in the share price.
RNS OUT
Big spread will be putting some off.
Ctw. I am probably rather more optimistic than my last post suggests but I do find the divergence between the messaging and the cold hard numbers when they come out rather unsettling. As you say the commodity gloves is a big players’ game which I have never liked very much as it no doubt has razor thin margins.
If they do get to £8-9m revenue in the second half then 2023 could be very exciting. I don’t think SYM’s revenue is seasonal, more like uneven. £8-9m (per half year) should be some sort of basis for estimating revenue going forward. Indeed, as most of the new initiatives in H2 2022 are only starting part way through it might be expected that revenue could be a fair bit higher in 2023 (or at least underpinned) as the full impact comes through in 2023.
We will know better end Sept but I hope any update to guidance given is realistic and has an appropriate level of buffer in it. SYM should know that the golden rule is to surprise on the upside.
Hounddog. Agree with what you say about the commodity gloves and had the same thought myself. The ‘change of strategy’ explanation looks disingenuous. Much more likely that customers dried up post the height of the boom in PPE sales at the height of the pandemic. Probably our competed by bigger players. However, the d2p gloves will give us a competitive advantage when approved and launched. Meditech still teed up to give it early legs. So many other positive developments announced and pending, I can forgive the gloss put on the loss of commodity glove sales.
Completely agree ctw!
Definitely a sounder looking company than a year ago. Nearly averaged down but glad I didn’t after the recent sp performance. Happy to hold in the meantime and see what the next few months bring.
Contrasting views here - but any of us could be right. I swing back and forward on SYM. I retain some optimism because I think Bimbo d2p contract is likely to be big, the Rivulis relationship seems to be going well and I do think there will be more wins. But there are questions. Revenue did not “soften” in H1 it cratered - by 40% (£1.9m). Of this drop £1m was due to no, yes no, nil, sales of commodity gloves as waiting for EU regulatory approval to sell premium gloves. But that does not explain why SYM did not continue to sell the commodity gloves - lost customer, loss making, shipping charges? Similarly they compare d2p sales to H1 2021 saying a 300% leap but H2 2021 would be more appropriate and sales are about the same.
£11-12m revenue this year would get them to break even. But Bristow’s forecasting has been lousy. Last year around this time forecasting c£500k profit for 2021, became a c£700k loss just before Xmas and double that in the final audited results. Couldn’t even forecast 8 days. Partly blamed on £0.7m sales missing the accounting cut off (which will have gone into H1 2022).
Let’s hope for some good RNSs.
i like many are under water , as some can exercise warrants and make money they are lucky, share price has to go higher .
will this turn out to be a good company and return MY money/..?
if i had my time again i would not touch this company but hindsight is a wonder full thing .
here s hoping .
Same here.
All the years I've given them the benefit of the dought, unfortunately the people who have said there a lifestyle company are unfortunately right..
After 15 years I am losing the will to live.
Vincel/Sea Pearl, Eranova, Bimbo, Meditech, FDA…….
Oh, and the best…… Johnson & Johnson.
High priced ‘wealth of experience’ Directors.
I resisted before, but it really is a lifestyle company.
Looking at it another way, H2 2021 revs was about £4.26 m, despite lockdowns and other headwinds. Just double that and add H1 2022 of £3m gives you £11.52m, bang in the middle of the guidance figure you mention. Doubling H2 revenues doesn’t seem at all unrealistic based on what they have announced already, never mind the additional announcements they have suggested are likely to drop in H2. I think their confidence in meeting full year guidance is probably justified but, as you say, let’s see.
Guidance is for £11-12m revenue for the full year. H1 2022 has been £3m. So they are suggesting that they can triple revenue in the second half! We shall have to see.
Also seems that the Indorama entity they are JVing with (there are more than one) is part of Vincel aka Pearl aka Sea Salt. SYM’s ultimate future may be to be bought by Vincel.